Qure.ai received FDA 510(k) clearance for its artificial intelligence algorithm that assists providers with breathing tube placement.
The release that’s officially down Late December is the company’s third 510(k). The previous two FDA green lights were for its brain CT scan product.
Using X-rays of the chest, the qXR BT Algorithm can analyze the position of the breathing tube. It automates the measurement and can report accuracy to the clinician, who can then decide if the tube needs to be replaced.
“We are pleased with the FDA approval for qXR BT. Over the past two years, we have seen a need to reduce turnaround times and address workflow delays,” said co-founder and CEO Prashant Warier in a statement. “The need for immediate assistance for an overburdened medical staff is paramount to patients.”
Digital Health Platform Truepill has launched a COVID-19 testing coverage platform to support insurers who are now required to cover the cost of over-the-counter testing at home.
This platform will allow payers to develop mystery shopping sites for their members direct to consumers, with Truepill fulfilling and shipping orders.
The digital health company also has a COVID-19 focused one virtual care platform and a range of diagnostic and digital tools for the employer market.
In October it announced that this was the case raised $142 million in Series D funding.
Consumer Genetics Company 23andMe and pharmaceutical giant GlaxoSmithKline have extended their drug discovery collaboration through July 2023.
The partnership, which began in 2018 as GSK Having invested $300 million in the genetics startup, 23andMe will earn a one-time payment of $50 million to extend the partnership term.
The companies also announced that 23andMe has acquired a licensing option for their joint immuno-oncology antibody program, which is currently in Phase 1 studies. GSK will exclusively conduct the remainder of the development and later studies.
“The cooperation with GSK was very productive. In less than four years, through this collaboration, we have identified over 40 therapeutic programs and advanced an immuno-oncology antibody targeting CD96 into clinical development,” Kenneth Hillan, head of therapeutics at 23andMe, said in a statement.
“GSK’s decision to extend the exclusive target discovery phase of our collaboration for an additional year demonstrates the enthusiasm for our collaboration and the value our database offers for target identification and the advancement of new medicines based on human genetics. “
23andI went public last year through a merger with a special purpose vehicle. In October, the company delved deeper into healthcare when it announced plans to acquire telemedicine and online prescribing platform Lemonaid Health.
Earlier this month, it received FDA 510(k) clearance for a genetic test to detect an inherited marker of prostate cancer.
